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During the past decade, studies on the composition of human microbiota and its relation
to  the host became one of the most explored subjects of the medical literature. The devel-
opment  of high-throughput molecular technologies allowed a deeper characterization of
human microbiota and a better understanding of its relationship with health and disease.
Changes  in human habits including wide use of antimicrobials can result in dysregulation of
host–microbiome homeostasis, with multiple consequences. The purpose of this review is
to highlight the most important evidence in the literature of host–microbiome interactionsHuman and  illustrate how these intriguing relations may lead to new treatment and prevention
strategies.
fully  cultured and the majority of them are classiﬁed within
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
The term microbiota refers to an abundant and diverse pop-
ulation  of microorganisms such as bacteria and fungi that
reside  on body sites, with the highest concentration of these
organisms  found in the gastrointestinal tract. Indeed, humans
harbor  a complex community of microorganisms that out-
numbers  human cells by tenfold.1
Standard culture techniques are limited to fully charac-
terize  microorganisms within the microbiota, but nowadays,
modern  molecular techniques termed metagenomics are
available  to allow deep characterization of the microbiota
of  the nasal mucosa, oropharynx, skin, urogenital sites, and
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1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licençalower intestine. These methods rely on polymerase chain reac-
tion ampliﬁcation of 16S ribosomal RNA-encoding genes of the
microbiota,  followed by DNA sequencing.2
Projects such as the Human Microbiome Project3 have
already done much  to deﬁne the variability in the micro-
biota  from different body sites and in the microbiomes both
within  the same human subject and among different subjects.
By  applying metagenomics, it is estimated that the human
lower  intestinal microbiota contains at least 1800 genera and
15,000–36,000  species, most of which have never been success-– 7◦ andar, CEP 04231-030 São Paulo, SP, Brazil.
Firmicutes and Bacteroidetes phyla.4
The human intestinal microbiota matures over the ﬁrst
year  of life and has substantial and continuous effects
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Table 1 – Reviews addressing diseases and biologycal phenomena related to human microbiome.
Topics Effect of microbiota Ref.
Inﬂammatory bowel
diseases
In  individuals with a genetic susceptibility to inﬂammatory bowel diseases, abnormal microbial
colonization of the gastrointestinal tract might be the origin of such dysregulation.
8
Diabetes  and obesity Studies show the effect of gut microbiota on host metabolism by improving energy yield from
food and modulating dietary or the host-derived compounds that alter host metabolic pathways.
9
Neuropsychiatric illness Recent advances in our understanding of how the intestinal microbiota communicates with the
brain via this axis to inﬂuence brain development and behavior. This extended communication
system  might inﬂuence a broad spectrum of diseases, including irritable bowel syndrome,
psychiatric  disorders, and demyelinating conditions such as multiple sclerosis.
10
Colorectal  cancer Potential mechanisms of bacterial oncogenesis are presented, focus is given to the oncogenic
capabilities of enterotoxigenic Bacteroides fragilis
11
Asthma  Host’s innate sensing systems, combined with recently developed methods that characterize
commensal  and pathogenic microbial exposure, now allow a uniﬁed theory for how microbes
cause  mucosal inﬂammation in asthma.
12
Rheumatic diseases Microbiota may be involved in the pathogenesis of rheumatic diseases including altered epithelial
and mucosal permeability, loss of immune tolerance to components of the indigenous microbiota,
and  trafﬁcking of both activated immune cells and antigenic material to the joints.
13
Antibiotic  resistance Horizontal gene transfer in gut has the potential to inﬂuence the evolution of members of this
 the 
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pmicrobial community and to mediate
organisms  to potential pathogens.
n human health and physiological development, including
ietary  and nutritional processing,5 prevention of pathogen
nvasion,6 and immune system maturation (Table 1).7
hanging  in  microbiota
uman behavior inﬂuences the composition of microbiota
nd  its continuous changes may  be responsible for the modi-
cation  of the ancient microbiota. Some authors believe that
iseases  succeed and fail in response to mankind’s advances.
he  appearance and disappearance of infectious and chronic
iseases  might be related to changes in human ecology, result-
ng  in changes in the microbes that populate our bodies.15
Human civilizations experienced many  transformations,
s improvement in sanitization that was  implemented to
educe  transmission of infections. In order to provide food
or  an increasing population, food production incorporated
ew strategies, such as extensive use of pesticides, antibiotics,
nd  hormones in animals and agriculture.15,16 The increas-
ng  antibiotic use in humans and farming is one of the most
mportant  fact that leads to a rapid and sometimes irreversible
hange  on human microbiota.17
Helicobacter pylori is an example of an ancient human micro-
iota  member that presented a dramatic change. H. pylori has
een  extensively investigated by Dr. Blaser et al. who observed
hat  this bacterium was  progressively disappearing during the
wentieth  century, from individuals in developed countries,
ith  secondary alterations in gastric secretory, hormonal and
mmune  physiology.18
This bacterium is thought to be related to peptic ulcer and
astric  cancer but the sustained acidity in H. pylori-negative
osts increases the risk of gastroesophageal reﬂux disease
nd  its consequences, including esophageal and gastric cardia
denocarcinomas.19The stomach also produces adipokine hormones known as
hrelin  and leptin, both with multiple roles in energy homeo-
tasis.  Patients under antibiotic treatment that eliminated H.
ylori  had increased circulating ghrelin levels.20 There is aspread of antibiotic resistance genes from commensal
hypothesis that in recent generations of children growing up
in  developed countries, there has been little gastric H. pylori-
mediated  regulation of those adipokines at the developmental
stage, when long-term adiposity is being programmed. It is
possible  that the disappearance of H. pylori might be con-
tributing  to the current epidemics of early-life obesity, type
2  diabetes and related metabolic syndromes.
Gordon et al. were also interested in studying the rela-
tionship between obesity and microbiome. They analyzed
fecal  samples of lean and obese twins and observed that
obesity  was  associated with phylum-level changes in the
microbiota, reduced bacterial diversity and altered represen-
tation  of bacterial genes, and metabolic pathways related to
glycoside hydrolases.21 Cardiovascular risk also has inﬂuence
on  intestinal microbial metabolism, as shown by Hazen et
al.,  who observed an increase in a proatherosclerotic metabo-
lite,  trimethylamine-N-oxide (TMAO), in healthy participants
after  the suppression of intestinal microbiota with oral broad-
spectrum  antibiotics.22
Stimulation of the immune system is another impor-
tant  function of the microbiome where the disruption of
immune  homeostasis may  be associated with inﬂamma-
tory  and atopic diseases.23 Epidemiological studies show that
H.  pylori-positive individuals have lower risk of childhood
asthma, allergic rhinitis and skin allergies than those with-
out  H. pylori.24 H. pylori-positive stomach has a rich population
of  immune cells which regulates immune functions. Stom-
achs  of H. pylori-negative hosts have much  lower number of
these  cells, which have systemic, as well as local activities.25
The increase in prevalence of immunological disorders (both
of  autoimmune and of atopic origin) in the developed world
has  been associated with changes in microbiome, which gave
support  to the hygiene hypothesis.26Microbiome  and  infectious  diseases
The relationship between the microbiome and infectious dis-
eases has yet to be determined. There is a lot of interest
i s . 2 0
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regarding the effect of antibiotic therapy, as antibiotic treat-
ment  to prevent or eradicate a pathogenic infection also
impacts  the composition of the commensal microbiota.
Combined antibiotic therapy with clarithromycin and
metronidazole reduced bacterial diversity of healthy subjects
in  short and long terms.27 A decline trend was  observed in
Actinobacteria in both throat and feces immediately after
treatment. The microbiota remained perturbed in some cases
for  up to four years post treatment.27 The effect of two courses
of  ciproﬂoxacin therapy was  analyzed by another study. A pro-
found and rapid shift in community composition occurred
within  three to four days of drug initiation, with a loss of
bacterial  diversity. One week after the end of each course,
communities returned incompletely to their initial state.28
The consequences of antibiotic therapy might be difﬁcult to
understand  as the microorganisms that are affected may  not
be  those that are directly targeted by the antibiotic. A com-
plex  network of co-dependence exists among members of the
microbiota,  driven by different ways. One intriguing interac-
tion  was  described by Hogan et al.29 that described a quorum
sensing molecule (3-oxo-C12 homoserine lactone), produced
by  Pseudomonas aeruginosa, that inhibits Candida albicans ﬁla-
mentation  and its virulence in vitro.
The microbiota has also protective functions. A mouse
model for S. typhimurium diarrhea was  used to study the role
of  microbiota and secretory antibodies (sIgA). When exposed
o  infection, mice that harbor a low complexity gut ﬂora, lack
S.  typhimurium colonization resistance and develop a normal
sIgA  response, but fail to clear it from the gut lumen. In these
mice,  pathogen clearance was  achieved by transferring a nor-
mal  complex microbiota. This study was  able to determinate
the  capacity of microbiota to confer colonization resistance
and  to mediate pathogen clearance in primary infections,
despite sIgA.30
Clostridium difﬁcile-associated diarrhea (CDAD) is possibly
one  of the most important examples in vivo on how antibi-
otics  affect the resident microbial ecosystem patient health.
Endogenous microbial inhabitants provide colonization resis-
tance  to infection by other microbes, most notably C. difﬁcile.
Until  now the therapeutic option for CDAD relies on antibi-
otic  treatment with vancomycin or metronidazole, but this
approach  was  associated with depletion of host microbiota
and  recurrence of symptoms in 35% of patients.31 Transplan-
tation  of indigenous microbiota was  tested as an alternative
treatment to restore the microbiota of a patient with CDAD.
Not  surprising, the intestinal microbiota transplantation
approach resulted in resolution rate of 94%, statistically supe-
rior  to vancomycin-containing regimens (p < 0.01).32
Use of probiotic is an intervention that seeks the
restoration of the beneﬁcial microbiota. Strategies are being
implemented following antibiotic therapy in infants with
necrotizing enterocolitis (NEC),33 as well as in individuals
being treated for antibiotic associated diarrhea,34 and bacte-
rial  vaginosis.35
Understanding the importance of microbiome is also
critical  given the huge number of microorganisms in this
ecosystem, and the possibility of gene transfer between
species. Transfer of resistance genes may  occur through
horizontal gene transfer (HGT) from commensal bacteria
to  opportunistic pathogens, as previously described CTX-M 1 4;1  8(6):660–663
extended-spectrum beta-lactamase (ESBL) resistance genes,
which  originate from Kluyvera sp.36 Using functional metage-
nomic  methods, Sommer et al.37 studied individuals after
antibiotic treatment and found clones conferring resistance to
13 different antibiotics and enabled the discovery of 95 unique
inserts  containing functional antibiotic resistance genes. The
majority  of these genes were  evolutionarily distant from
known  resistance genes, including 10 previously unidentiﬁed
beta-lactamase gene families.
Because of the harmful effects of antibiotics on the
commensal microbiota, alternative therapies are under
investigation, as antimicrobial peptides that have potential
antibiotic adjunctive action. For instance, a reduced produc-
tion  of the antimicrobial peptide REG3 was  related to an
increased  colonization by vancomycin-resistant Enterococcus
(VRE)  in mice. This was a consequence of depleted microbial
signals38 in activating Toll-Like Receptors (TLR). This mecha-
nism  seems to be involved in bacterial-mediated protection
from  diseases, including VRE, suggesting that TLR agonists
could  be administered during antibiotic therapy to help restore
immune  homeostasis, speciﬁcally REG3 expression, drasti-
cally  reducing colonization by VRE.39
The challenge of efﬁcient control strategies for multidrug
resistant organisms (MDROs) brought the attention for the
hypothesis  that restoring and maintaining the commensal
microbiome may  be a key to prevent MDRO colonization and
infection.40 Conversely, a comprehensive antimicrobial stew-
ardship  program focusing the prevention of MDRO  emergence
is  needed. In an attempt to identify antibiotics that promote
KPC  colonization, Perez et al.41 evaluated whether antibiotics
promote colonization by KPC-producing Klebsiella pneumonia
(KPC-Kp). They found that those antibiotics that fully suppress
anaerobes and bacteroides (i.e. tigecycline, clindamycin and
piperacillin-tazobactam) promoted signiﬁcant colonization by
KPC-Kp, whereas agents that did not suppress total anaerobes
or  bacteroides (i.e., ertapenem, ciproﬂoxacin and cefepime) did
not.41
With an increasing number of studies demonstrating that
antibiotics  have detrimental effects on the host health and on
host colonization there is urgent need to develop treatments
targeting speciﬁc pathogens without changing the indige-
nous  microbiota. For this, a better understanding on microbial
cross-talking is essential. Most of the studies are still experi-
mental  and remain to be validated, but they hold substantial
promise as adjunct therapies to antibiotics in a promising
future.
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